Breaking News

Takeda Invests $765M in Mfg. Facility for Plasma-Derived Therapies in Japan

The new site increases the capacity of Takeda’s current plasma manufacturing site in Narita, Japan almost five-fold.

Takeda is investing approximately $764.6 million to build a new manufacturing facility for plasma-derived therapies (PDTs) in Osaka, Japan. This represents Takeda’s largest ever investment in manufacturing capacity expansion in Japan. The investment aligns with Takeda’s capital allocation policy of “Investing in Growth Drivers”, through disciplined and focused investments in value-creating business opportunities, enabling Takeda to establish a world-class end-to-end manufacturing facility for...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters